Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Kazia Therapeutics Limited American Depositary Shares

KZIA

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Last trade $5.36
Day change -$0.24 (-4.29%)
Day range $5.27 – $5.81
Volume 445,991
Market cap $87M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for KZIA.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for KZIA.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight

Over 200 companies are advancing 220+ pipeline glioblastoma drugs across various clinical development stages. The pipeline is shifting from conventional chemotherapy toward targeted therapy, immunotherapy, and epigenetic approaches. Key candidates include Kazia Therapeutics' Paxalisib (Phase III), BPG Bio's BPM31510, and immunotherapy programs from Inovio Pharmaceuticals. Recent developments include Telix's first radiopharmaceutical therapy entering Phase III trials and multiple clinical collaborations announced in early 2026.

Benzinga

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

Kazia Therapeutics Limited (NASDAQ: KZIA) announced the appointment of James Levine as Chief Financial Officer, effective June 1, 2026. Levine brings over two decades of experience in investment banking and biotech financial leadership, including previous CFO roles at Cardiff Oncology and Cidara Therapeutics, where he led major pharmaceutical partnerships. His appointment is expected to support Kazia's advancement of its lead asset paxalisib across multiple cancer indications and pipeline development.

GlobeNewswire Inc.

Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight

The glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and others are advancing innovative immunotherapies, targeted treatments, and personalized medicine approaches to address the poor prognosis of this aggressive brain tumor.

Benzinga

Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform

Kazia Therapeutics announced the in-licensing of a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer. The lead candidate MSETC is designed to restore immune signaling in tumors resistant to immunotherapy. Kazia plans to advance the SETDB1 program alongside its PD-L1 degrader platform to IND readiness within 18 months at an estimated cost of $6 million, leveraging shared resources and expecting to qualify for Australian R&D tax incentives.

Benzinga

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Kazia Therapeutics announced that its CEO will participate in the J.P. Morgan Healthcare Conference week in San Francisco. The company expects to provide a clinical and translational update before month-end from its Phase 1b trial evaluating paxalisib in advanced triple-negative breast cancer, including additional clinical response observations and expanded biomarker analyses. Kazia also plans to provide the first update on its potential first-in-class PD-L1 protein degrader program.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 17, 20251-for-5reverse split
Oct 28, 20241-for-10reverse split
Jul 14, 20171-for-4reverse split